Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged 18 to 80 years inclusive~* Subjects with an Overall Disease Severity of 3 (moderate)~* Subjects with 3% - 10% treatable BSA (Body Surface Area) excluding scalp, face, groin, axillae and/or other intertriginous areas~* For concurrent medications, type and dose must have been stable for at least 3 months prior to study entry and not expected to change during the study. Subjects receiving treatment with beta-blockers or lithium, whose dose has been stable for at lest 6 months and who have shown no worsening of their psoriasis, may be included in the study, at the discretion of the investigator~Exclusion Criteria:~* Subjects with intakes of more than 2,000 IU/day (50 mcg/day) of vitamin D (tolerable upper intake level) and/or more than 1,000 mg/day of calcium~* Subjects whose psoriasis involves only the scalp, face, groin, axillae, and/or other intertriginous areas~* Subjects with a wash-out period for topical treatment less than 30 days (Any steroid containing medication, dovonex, anthralin, tar and/or UVB treatment)~* Subjects with a wash-out period for systemic treatment less than 12 weeks (corticosteroids, biologics and/or PUVA treatment; Examples of these therapies include, but are not limited to PUVA, Soriatane, Cyclosporine, Hydroxyurea, Mycophenolate mofetil, Sulfasalazine, Azathioprine, Alefacept, Efalizumab, Adalimumab, Etanercept, Infliximab, Rituximab, and Methotrexate)~* Subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis~* Subjects who foresee intensive UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1) Vectical™ Ointment and Clobex® Spray (Type: OTHER): Vectical™ Ointment weekdays \& Clobex® Spray weekends regimen
- 2) Clobex® Spray and Vectical™ Ointment (Type: OTHER): Clobex® Spray morning and Vectical™ Ointment evening regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).